Clinical trials: Patients With Tumor
Leukemia, Leukemia, Lymphocytic, Chronic
A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding…
- Trial name
- NCT00076401
- Testing
- Motexafin gadolinium
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Pharmacyclics LLC.
Solid Tumor Malignancies
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
This protocol will examine the safety of intravenous administration of Clostridium novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C.
- Trial name
- NCT01118819
- Testing
- Clostridium novyi-NT spores
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- BioMed Valley Discoveries, Inc
Solid Tumor, Advanced Solid Tumor
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
This is a Phase 1, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy…
- Conditions
- Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer, Colo-rectal Cancer
- Trial name
- NCT05578092
- Testing
- MRTX0902, MRTX849
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Mirati Therapeutics Inc.
Cutaneous Metastatic Melanoma
Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma
This device phase I/II, first in human, early feasibility study (EFS), open-label, single-arm trial aims to evaluate the safety, tolerability, and preliminary efficacy of Gold Nanorod (GNR)-enabled sub-ablative targeted…
- Trial name
- NCT06870994
- Testing
- Targeted Hyperthermia Therapy
- Volunteers
- 10 people
- Sponsor
- Sona Nanotech Inc
Solid Tumors, ER+ Breast Cancer
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
- Conditions
- Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation
- Trial name
- NCT05490472
- Testing
- JAB-2485 (Aurora A inhibitor)
- Where
- 8 sites in United States, China
- Volunteers
- 102 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Breast Cancer
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
This is a Phase III, randomized, double-blind, parallel, multi-center trail to evaluate the efficacy and safety of TQB3616 capsule combined with endocrine compared to placebo compared with endocrine in HR-positive and…
- Trial name
- NCT05780567
- Testing
- TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
- Where
- 3 sites in China
- Volunteers
- 1,946 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Neoplasms
A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies
To evaluate the safety (adverse events and dose-limiting toxicity) of daily oral doses of ZSTK474 in patients with advanced solid malignancies.
- Trial name
- NCT01682473
- Testing
- ZSTK474
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Zenyaku Kogyo Co., Ltd.
Superficial Bladder Cancer
Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer
The aim of this phase Ib/IIa study is to investigate the maximum tolerable concentration of abnobaVISCUM® Fraxini for intravesical instillation in patients with superficial bladder cancer.
- Trial name
- NCT02007005
- Testing
- abnobaVISCUM Fraxini
- Where
- 2 sites in Egypt, Germany
- Volunteers
- 37 people
- Sponsor
- Abnoba Gmbh
Non-small-cell Lung Cancer, Squamous Cell Carcinoma
Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
The purpose of this study is to compare effectiveness and safety of experimental anticancer medicine, AXL1717, and docetaxel in patients with squamous cell carcinoma or adenocarcinoma of the lung.
- Conditions
- Non-small-cell Lung Cancer, Squamous Cell Carcinoma, Adenocarcinoma of the Lung
- Trial name
- NCT01561456
- Testing
- AXL1717, Docetaxel
- Where
- 24 sites in Belarus, Hungary and 3 more
- Volunteers
- 100 people
- Sponsor
- Axelar AB
Metastatic Cancer
In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides
The purpose of this study is to evaluate in vitro the potential of peptides, to modify, phenotypically and functionally, the monocyte-derived dendritic cells of patients with metastatic cancer.
- Trial name
- NCT02159937
- Testing
- Blood sampling by vena punction.
- Where
- Brazil
- Volunteers
- 33 people
- Sponsor
- Recepta Biopharma
Solid Tumor, Adult
Study of DF9001 in Patients With Advanced Solid Tumors
DF9001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases.
- Trial name
- NCT05597839
- Testing
- DF9001, KEYTRUDA® (pembrolizumab)
- Where
- 17 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dragonfly Therapeutics
Psoriasis
A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis
In recent years, biologics have changed the treatment of psoriasis, giving us additional therapeutic options that are potentially less toxic to the liver, kidneys, and bone marrow and are not teratogenic.
- Trial name
- NCT01126619
- Where
- 25 sites in Turkey (Türkiye)
- Volunteers
- 103 people
- Sponsor
- Abbott
Non-hematologic Malignancy
A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
The purposes of this study are to evaluate the safety and tolerability of sapanisertib (MLN0128) milled active pharmaceutical ingredient (API) capsules administered both as a single agent and in combination with paclitaxel, to…
- Trial name
- NCT02412722
- Testing
- Sapanisertib, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-Hodgkin Lymphoma, Neoplasms
A Study to Investigate the Effects of Ketoconazole on LBH589 in Patients With Advanced Solid Tumors
The primary purpose of this open-label study is to investigate the interaction of ketoconazole, a liver enzyme inhibitor, on oral LBH589 in adult patients with advanced solid tumors.
- Trial name
- NCT00503451
- Testing
- LBH589
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Cancer, Gastric Cancer
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- Minnelide 101 (NCT03129139)
- Testing
- Minnelide™Capsules
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Minneamrita Therapeutics LLC
Leukemia, Myeloid
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
- Conditions
- Leukemia, Myeloid, Acute, Newly Diagnosed
- Trial name
- NCT05673057
- Testing
- MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A, MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax
- Where
- 9 sites in France, Lithuania and 2 more
- Volunteers
- 80 people
- Sponsor
- Molecular Partners AG
Breast Neoplasms, Neoplasm Metastasis
Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
This study will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and vinorelbine therapy in patients with HER-2 overexpressing metastatic breast cancer.
- Trial name
- NCT00426530
- Testing
- everolimus (RAD001)
- Where
- 6 sites in Belgium, France and 3 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia
Patients with MGIN, HGIN or flat-type early SCCA of the esophagus will be treated on 3 month intervals with Radiofrequency Ablation (RFA) until complete eradication (CR: no MGIN or worse in the biopsies) will be achieved.
- Trial name
- NCT02047305
- Testing
- Radiofrequency Ablation
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Covidien, GI Solutions
Solid Tumours, Sarcoma
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which…
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
- Trial name
- INVOKE (NCT06789172)
- Testing
- OKN4395, Pembrolizumab, Fasting
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Epkin
Solid Tumor
Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China
Main purpose: To evaluate the safety and tolerability of BAT6021 injection in the treatment of locally advanced or metastatic solid tumors with single drug or combined with tislelizumab(anti PD-1 monoclonal antibody); Explore the…
- Trial name
- NCT05120375
- Testing
- BAT6021
- Where
- 3 sites in China
- Volunteers
- 5 people
- Sponsor
- Bio-Thera Solutions
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.